For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240927:nRSa0770Ga&default-theme=true
RNS Number : 0770G Eco Animal Health Group PLC 27 September 2024
27 September 2024
ECO Animal Health Group plc
("ECO" or the "Company")
Result of Annual General Meeting
ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health
company with a portfolio of marketed veterinary products and a maturing
proprietary R&D pipeline, announces that at its Annual General Meeting
held yesterday all resolutions proposed to the meeting were duly passed.
Votes received in relation to each resolution were as follows:
Resolution For Against
% Discretionary % %
01 41,070,268 100.00 Nil 0.00 Nil 0.000
02 36,456,852 88.768 Nil 0.00 4,613,165 11.232
03 40,961,390 99.735 Nil 0.00 108,878 0.265
04 34,395,129 84.081 Nil 0.00 6,511,866* 15.919
05 41,070,404 99.999 Nil 0.00 541 0.001
06 40,976,766 99.771 Nil 0.00 94,179 0.229
07 40,945,821 99.709 784 0.002 118,663 0.289
08 40,957,821 99.726 784 0.002 111,663 0.272
09 41,046,763 99.941 7,500 0.018 16,682 0.041
* Note: The Board has been informed that a shareholder holding a block of
1,902,729 votes incorrectly lodged a proxy in respect of these shares against
resolution 4. This shareholder acknowledged that the intent had been to
vote these shares in favour of resolution 4.
-Ends-
For further information please contact:
ECO Animal Health Group plc 020 8447 8899
David Hallas (CEO)
Christopher Wilks (CFO)
Singer Capital Markets (Nominated Adviser & Joint Broker) 020 7496 3000
Phil Davies
Sam Butcher
Investec (Joint Broker) 020 7597 5970
Gary Clarence
Lydia Zychowska
Equity Development 020 7065 2692
Hannah Crowe
Matt Evans
ICR Consilium (Financial PR) 020 3709 5700
Mary-Jane Elliott ecoanimalhealth@consilium-comms.com
Jessica Hodgson
About ECO Animal Health
ECO Animal Health is a world leader in animal health, developing and marketing
branded veterinary pharmaceuticals globally, with expertise in antibiotics and
vaccines for pigs and poultry. We have a maturing proprietary R&D
pipeline.
Headquartered in the UK, with global offices including R&D and
manufacturing, we have marketing authorisations in over 70 countries and
employ over 200 people worldwide.
Our lead product, Aivlosin® is a proprietary, patented medication which is
effective against both respiratory and intestinal diseases in pigs and
poultry.
Click here for more information: https://ecoanimalhealth.com
(https://ecoanimalhealth.com/)
( )
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END RAGSEUFDWELSEFU